| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3922 |
| Trial ID | NCT06479356 |
| Disease | Non-Hodgkin's Lymphoma | Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Location approved | China |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL |
| Year | 2024 |
| Country | China |
| Company sponsor | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Other ID(s) | JWCAR029-117 |
| Cohort 1 | |||||||||
|
|||||||||